Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 29, 2021

View Archived Issues

THAP1 gene variation associated with neurodevelopmental disorders and impaired myelination

CD300a blockade ameliorates neuronal deficit after ischemic stroke

Adding MGMT-modified gamma-delta T cells to temozolomide in models of high-grade gliomas

Jiangsu Chia Tai Tianqing Pharmaceutical Group patents HBV HBsAg secretion inhibitors

New IL-17 modulators discovered at UCB

Agios Pharmaceuticals, University of Michigan present menin/MLL interaction inhibitors

Camp Therapeutics identifies new antibacterial peptides

Bayer describes new anthelmintic compounds

New PKP2-based gene therapy for ARVC treatment

Novel AChE/GSK-3beta inhibitor shows promising activity in models of AD

IACTA Pharmaceuticals receives funding to conduct preclinical studies of IC-800

IL-2 partial agonist allows T-cell expansion without differentiation

Researchers develop a novel rotenone-induced murine model of bipolar disorder

Gene therapy provides pain relief by resetting "corrupted" circuit

New AAV/CRISPR strategy corrects complex genetic defects in a severe hemophilia B model

Single-cell atlas of SCLC tumors identifies plasticity, metastasis, and immunosuppression signatures

Dual-targeting CAR-T cell strategy provides sustained antitumor activity and prevents tumor escape

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...